Loading…
Study demonstrated platform's ability to detect renal neural activity changes.
Autonomix Medical, Inc. (Nasdaq: AMIX) announced on July 24, 2026, positive results from a preclinical study. The study evaluated the company's proprietary neural sensing platform, which successfully detected, localized, and confirmed changes in renal neural activity.
The platform's performance in the preclinical setting indicates its potential for further development and application in medical devices. Autonomix Medical has a free float of 526,438 shares and 543,000 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.